Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs

DIB ALICIA ; PAREDES ALEJANDRO; ELIÓPULOS NATASHA; FARÍAS CRISTINA; SUÁREZ GONZALO; ALDROVANDI ARIEL ; PALMA SANTIAGO ; ALLEMANDI DANIE; LANUSSE CARLOS; SÁNCHEZ BRUNI SERGIO

Clin Exp Pharmacol

OMICS International

Año: 2015 vol. 5

he aim of this study was to evaluate the influence of different matrices developers on the pharmacokinetic behavior of Ricobendazole (RBZ) controlled release (CR) formulations and test their correlation in vitro-in vivo, using one Albendazole (ABZ)-based and one RBZ-based immediate-release formulation as references. The main excipients used for CR formulations were Hydroxypropyl Methyl Cellulose, Cetyl Alcohol, Gelucire 50/02® and Alginic Acid. Pharmacotechnical quality control tests were successfully completed. Twelve parasite-free no pregnant dogs were randomly divided into six groups and received different treatments (single oral doses) using an incomplete block design (two phases) (n=4). Phase I: treatment "A" (ABZ-based immediate-release formulation [25mg/kg]). Treatment "B" (RBZ-based immediate release formulation [20 mg/kg]) and treatments from "C" to "F" (CRformulations [20 mg/kg]). Phase II was performed after 21 days of